| Indication for HDMTX |
|
| Non-Hodgkin lymphoma |
41% |
| Osteosarcoma |
30% |
| Acute lymphoblastic leukemia |
23% |
| Other malignancy |
7% |
| Median pretreatment MTX concentration |
17μM |
| Median time of glucarpidase dose following MTX administration |
3 days |
| Total glucarpidase doses |
|
| 1 dose |
76% |
| 2 doses |
22% |
| 3 doses |
2% |
| Median reduction in baseline serum MTX after first glucarpidase dose by HPLC (n = 156) |
|
| At 15 minutes |
99% |
| At 40 hours |
99% |
| Adverse events |
|
| Paresthesia |
2.0% |
| Flushing |
1.8% |
| Headache |
1.0% |
HDMTX = high-dose methotrexate; HPLC = high-performance liquid chromatography; MTX= methotrexate [36]